Background
Small cell carcinoma occurs mainly in the lung, which occupies about 15–20% pulmonary malignant tumors. Besides, this disease could also exist in extra pulmonary sites, such as skin, gastrointestinal and urinary tract [
1,
2]. Small cell carcinoma of the bladder (SCCB) accounts for 0.35–0.7% of bladder tumors and indicates aggressive biological behavior and poor prognosis [
3]. SCCB is usually admixed with other pathological subtypes, like urothelial carcinoma and squamous cell carcinoma [
4]. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer related death in men around the world. Nevertheless, coexistence of SCCB and prostate adenocarcinoma in one patient was extremely scarce, which brought certain challenges to the treatment and prognosis of patients [
5,
6]. Here, we described two cases of such rare malignancy who underwent surgery in our institution.
Discussion and conclusion
In present study, we described two unusual SCCB cases with combination of prostate adenocarcinoma. HE and IHC staining of tissue sections with demonstration of NSE, CgA, Syn, P504s and PSA supported the diagnosis. Prostate cancer is the most common malignancy in men and a major cause of cancer deaths in western countries [
7]. SCCB is extremely infrequent with a proportion about 0.35–0.7% of all bladder tumors, and has a tendency to present with mixed histological accompaniments, like squamous cells, transitional cells and urothelial carcinoma [
3,
8]. SCCB has an evident male predominance (male: female = 7: 1) with an average age of 60–80 years [
9]. The mechanism of SCCB is still controversial at present. The most widely accepted theory is that it derives from multi-potential stem cells. Such conjecture could also explain the phenomenon that more than half of SCCB coexisted with other histological patterns [
10]. The second theory considers that SCCB originates from neuroendocrine cells among the urothelial cells, just like the enterochromaffi cells in the intestinal tract. Another theory suggests it arises from the neuroendocrine cells within the normal or metaplastic urothelium [
3,
11].
Bladder tumors often cause hematuria, so unusually subtype of tumors should be kept in mind, especially in elderly patients [
12]. Gross hematuria is the most common symptom in SCCB because of the ulcerative growth of invasive lesion into bladder wall. Both the two patients presented with gross hematuria, and odynuria/dysuria. Paraneoplastic syndromes (hypercalcaemia, Cushing syndrome, sensory neuropathy and so on) were commonly in patients of small cell carcinoma of prostate or lung, extremely rare in SCCB [
4]. Prostate tumor often cause the elevation of PSA level. According to pre-operative serum chemistries, both patients had higher PSA level than normal (4 ng/ml). Macroscopically, SCCB is usually round or oval without pedicles, and infiltrates into the bladder wall [
13]. It is difficult to diagnose SCCB by clinical manifestation or imaging examination. The diagnosis of SCCB mainly depend on histopathological examination. Small and round-shaped cancer cells are representative features of SCCB. Meanwhile, the nest-like structures, overlapping nucleoli, scarce cytoplasm, tumor necrosis and substantial mitotic images are also commonly seen. Neuroendocrine markers are typical for small cell carcinoma, including Syn, NSE and CgA. The appearance of disorder of glands structure, glandular hyperplasia, cell atypia, invasive growth pattern and positive expression of P504S and PSA are essential for the diagnosis of prostate adenocarcinoma [
14,
15]. As shown in Figs.
2 and
4, all these pathological characteristics were observed in the resected tissues.
SCCB tends to metastasize to lymph nodes and distant organs early. Koay et al. [
16] analyzed 642 SCCB patients and found muscular layer infiltrated in > 90% cases and lymphatic or distant organic metastasis in > 80% cases. But in this study, no obvious metastatic lesions were detected via pre-operative examinations. Proven treatments for SCCB have been explored over the years, while no significant progress has been verified. The curative strategy of SCCB is similar to that of small cell lung cancer (SCLC), with comprehensive treatment including surgery, chemotherapy and radiation therapy. Howbeit, no standard therapeutic regimens have been established currently, and the treatment depends on the stage and progress of SCCB basically [
4,
17]. Transurethral resection of bladder tumors (TUR-BT) is not effective enough in controlling SCCB progression, even for localized lesions. Siefker et al. [
18] compared the effects of different cooperative therapy (neoadjuvant chemotherapy + surgery vs. surgery + post-operative chemotherapy) for SCCB and found the 5-year survival rates of two groups were 78 and 36%, respectively. Pre-neoadjuvant chemotherapy was able to prolong the survival time of SCCB patients significantly (
p < 0.05). Carranza et al. [
19] also agreed with the benefit of neoadjuvant chemotherapy according to their clinical experience. Pre-neoadjuvant chemotherapy was not used in our study because we could not know the accurate pathological subtype of tumor lesions before operation. Radical cystectomy plus chemotherapy is the most widely used treatment for localized SCCB. At present, cisplatin, cyclophosphamide, VP16 and Adriamycin are frequently used and combined regimen is proven better than monotherapy [
20]. Mixed SCCB had a good response to the MVAC protocol (methotrexate + vincristine + adriamycin + cisplatin), while pure SCCB responded to cisplatin-etoposide or ifosfamide/adriamycin regimen better. Since cisplatin has strong side effects of nephrotoxicity and neurotoxicity, it is feasible to choose carboplatin instead of cisplatin in patients with poor conditions [
3,
21]. In our study, both patients accepted CE-based chemotherapy regimens after surgery.
Radical prostatectomy (RP) is the optimal strategy for limited prostate cancer. Biochemical recurrence (BCR) is defined as consecutive serum PSA > 0.2 ng/ml twice after RP [
22]. Proper treatment for BCR after RP is still controversial, the usual options include radiotherapy of prostate region, anti-androgen drugs in combination with 5α-reductase inhibitors, chemotherapy and observational waiting [
22]. In our study, one patient progressed to BCR with successive post-operative serum PSA of 0.34 and 0.55 ng/ml. This patient only took Bicalutamide orally for remedy because of physical and financial reasons, and died of liver and lung metastasis 8 months after operation eventually. Owing to the lack of post-mortem pathological examination, we are not clear whether the metastatic foci derived from prostate adenocarcinoma or SCCB. The other patient just underwent CE chemotherapy regimen after surgery and no BCR of prostate cancer or distant metastasis was detected after a follow up of 19 months.
In conclusion, We reported two extremely unusual cases of coexistence of SCCB and prostate adenocarcinoma and reviewed relative articles in this paper. SCCB is an infrequent pattern of neuroendocrine tumor with low differentiation and high malignancy. There are still many “blind areas” for its pathogenesis, diagnosis and treatment. Although a variety of therapeutic measures are applied currently, the mortality rate of SCCB patients remains high. The discovery of specific diagnostic method and optimal remedial policy should be the keynotes of future research.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.